Aligos Therapeutics (ALGS) Earnings Date, Estimates & Call Transcripts $42.20 +2.86 (+7.27%) (As of 01:09 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Aligos Therapeutics Latest Earnings SummaryActual EPS (Nov. 6) -$3.07 Missed By -$0.92 Consensus EPS (Nov. 6) -$2.15 Aligos Therapeutics released Q3 2024 earnings on November 6, 2024, reporting an EPS of -$3.07, which missed the consensus estimate of -$2.15 by $0.92. Quarterly revenue was reported to be $1.27 million, above analyst estimates of $1 million. With a trailing EPS of -$13.32, Aligos Therapeutics' earnings are expected to decrease next year, from ($10.36) to ($11.92) per share. Get Aligos Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALGS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALGS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Aligos Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.19-$0.19-$0.19Q2 20241-$0.16-$0.16-$0.16Q3 20242-$4.40-$0.17-$2.29Q4 20242-$1.83-$0.19-$1.01FY 20246-$6.58-$0.71-$3.65Q1 20251-$1.85-$1.85-$1.85Q2 20251-$1.95-$1.95-$1.95Q3 20251-$2.13-$2.13-$2.13Q4 20251-$2.19-$2.19-$2.19FY 20254($8.12)($8.12)($8.12) Aligos Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/6/2024Q3 2024-$2.15-$3.07 -$0.92-$3.07$1.00M$1.27M8/6/2024Q2 2024-$4.00$0.75+$4.75$0.03-$1.06M5/7/2024Q1 2024-$4.75-$5.50 -$0.75-$0.22-$0.99M3/12/2024Q4 2023-$6.75-$5.50+$1.25-$0.22$3.20M$2.68M11/2/2023Q3 2023-$12.00-$10.25+$1.75-$0.41$5.00M$2.15M8/3/2023Q2 2023-$12.50-$10.75+$1.75-$0.43-$6.89M Get the Latest News and Ratings for ALGS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$12.25-$13.25 -$1.00-$0.53$4.30M$2.72M3/9/2023Q4 2022-$12.25-$12.75 -$0.50-$0.51$2.80M$3.54M Aligos Therapeutics Earnings - Frequently Asked Questions When did Aligos Therapeutics announce their last quarterly earnings? Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earning data on Wednesday, November 6, 2024. Learn more on ALGS's earnings history. Did Aligos Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aligos Therapeutics (NASDAQ:ALGS) missed the analysts' consensus estimate of ($2.15) by $0.92 with a reported earnings per share (EPS) of ($3.07). Learn more on analysts' earnings estimate vs. ALGS's actual earnings. How much revenue does Aligos Therapeutics generate each year? Aligos Therapeutics (NASDAQ:ALGS) has a recorded annual revenue of $6.00 million. How much profit does Aligos Therapeutics generate each year? Aligos Therapeutics (NASDAQ:ALGS) has a recorded net income of -$87.68 million. ALGS has generated -$13.32 earnings per share over the last four quarters. What is Aligos Therapeutics's EPS forecast for next year? Aligos Therapeutics's earnings are expected to decrease from ($10.36) per share to ($11.92) per share in the next year. More Earnings Resources from MarketBeat Related Companies Annexon Earnings Results Altimmune Earnings Results Ginkgo Bioworks Earnings Results Astria Therapeutics Earnings Results Tourmaline Bio Earnings Results Mereo BioPharma Group Earnings Results CorMedix Earnings Results Xeris Biopharma Earnings Results Phathom Pharmaceuticals Earnings Results Kodiak Sciences Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report Grab This Altcoin Before Trump's Crypto Announcement (Ad)Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. Click here to check it out now This page (NASDAQ:ALGS) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners$19 for a FULL YEAR of stock picks?!We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? ...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
